These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38811192)

  • 1. Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging.
    Suzuki A; Hayashi A; Oda S; Fujishima R; Shimizu N; Matoba K; Taguchi T; Toki T; Miyatsuka T
    Endocr J; 2024 Aug; 71(8):767-775. PubMed ID: 38811192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of empagliflozin on liver fat in patients with metabolic dysfunction-associated steatotic liver disease without diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Cheung KS; Ng HY; Hui RWH; Lam LK; Mak LY; Ho YC; Tan JT; Chan EW; Seto WK; Yuen MF; Leung WK
    Hepatology; 2024 Oct; 80(4):916-927. PubMed ID: 38536017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe hepatic steatosis promotes increased liver stiffness in the early stages of metabolic dysfunction-associated steatotic liver disease.
    Kumada T; Toyoda H; Ogawa S; Gotoh T; Suzuki Y; Sugimoto K; Yoshida Y; Kuroda H; Kamada Y; Sumida Y; Ito T; Akita T; Tanaka J
    Liver Int; 2024 Jul; 44(7):1700-1714. PubMed ID: 38558221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: A retrospective nationwide claims database study in Japan.
    Shikamura M; Takayama A; Takeuchi M; Kawakami K
    Diabetes Obes Metab; 2024 Aug; 26(8):3099-3109. PubMed ID: 38708591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effects of ipragliflozin and pioglitazone on metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow-up of a randomized, 24 week, active-controlled trial: Effect of ipragliflozin in MASLD.
    Ito D; Shimizu S; Haisa A; Yanagisawa S; Inoue K; Saito D; Sumita T; Yanagisawa M; Uchida Y; Inukai K; Shimada A
    J Diabetes Investig; 2024 Sep; 15(9):1220-1230. PubMed ID: 38775319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.
    Park HJ; Lee S; Lee JS
    Abdom Radiol (NY); 2024 Sep; 49(9):3036-3044. PubMed ID: 38587630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease.
    Bellanti F; Lo Buglio A; Dobrakowski M; Kasperczyk A; Kasperczyk S; Aich P; Singh SP; Serviddio G; Vendemiale G
    World J Gastroenterol; 2022 Jul; 28(26):3243-3257. PubMed ID: 36051336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Xing B; Zhao Y; Dong B; Zhou Y; Lv W; Zhao W
    J Diabetes Investig; 2020 Sep; 11(5):1238-1247. PubMed ID: 32083798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of SGLT2 Inhibitors on Type 2 Diabetes Mellitus With Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    Wei Q; Xu X; Guo L; Li J; Li L
    Front Endocrinol (Lausanne); 2021; 12():635556. PubMed ID: 34220701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus.
    Suzuki Y; Kaneko H; Okada A; Ohno R; Yokota I; Fujiu K; Jo T; Takeda N; Morita H; Node K; Yasunaga H; Komuro I
    J Endocrinol Invest; 2024 May; 47(5):1261-1270. PubMed ID: 38114769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dipeptidyl peptidase-4 inhibitor and sodium-glucose cotransporter 2 inhibitor additively ameliorate hepatic steatosis through different mechanisms of action in high-fat diet-fed mice.
    Iwamoto Y; Kimura T; Dan K; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Shimoda M; Nogami Y; Shirakiya Y; Nakanishi S; Mune T; Kaku K; Kaneto H
    Diabetes Obes Metab; 2024 Jun; 26(6):2339-2348. PubMed ID: 38504118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Favorable liver and skeletal muscle changes in patients with MASLD and T2DM receiving glucagon-like peptide-1 receptor agonist: A prospective cohort study.
    Kakegawa T; Sugimoto K; Saito K; Yunaiyama D; Araki Y; Wada T; Takahashi H; Yoshimasu Y; Takeuchi H; Itoi T
    Medicine (Baltimore); 2024 Jun; 103(23):e38444. PubMed ID: 38847728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin for Metabolic Dysfunction-Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial.
    Simon TG; Wilechansky RM; Stoyanova S; Grossman A; Dichtel LE; Lauer GM; Miller KK; Hoshida Y; Corey KE; Loomba R; Chung RT; Chan AT
    JAMA; 2024 Mar; 331(11):920-929. PubMed ID: 38502074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Canagliflozin on Hepatic Steatosis, Visceral Fat and Skeletal Muscle among Patients with Type 2 Diabetes and Non-alcoholic Fatty Liver Disease.
    Nishimiya N; Tajima K; Imajo K; Kameda A; Yoshida E; Togashi Y; Aoki K; Inoue T; Nakajima A; Utsunomiya D; Terauchi Y
    Intern Med; 2021 Nov; 60(21):3391-3399. PubMed ID: 33994437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
    Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
    Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Aso Y; Kato K; Sakurai S; Kishi H; Shimizu M; Jojima T; Iijima T; Maejima Y; Shimomura K; Usui I
    Int J Clin Pract; 2019 May; 73(5):e13335. PubMed ID: 30810254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Update on the Effect Of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease: A Systematic Review of Clinical Trials.
    Alfayez AI; Alfallaj JM; Mobark MA; Alalwan AA; Alfayez OM
    Curr Diabetes Rev; 2024; 20(2):e250523217349. PubMed ID: 37231725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.